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The application of computational and mathematical modelling to explore
the mechanics of biological systems is becoming prevalent. To significan-
tly impact biological research, notably in developing novel therapeutics,
it is critical that the model adequately represents the captured system.
Confidence in adopting in silico approaches can be improved by applying
a structured argumentation approach, alongside model development and
results analysis. We propose an approach based on argumentation from
safety-critical systems engineering, where a system is subjected to a strin-
gent analysis of compliance against identified criteria. We show its use
in examining the biological information upon which a model is based,
identifying model strengths, highlighting areas requiring additional bio-
logical experimentation and providing documentation to support model
publication. We demonstrate our use of structured argumentation in the
development of a model of lymphoid tissue formation, specifically Peyer’s
Patches. The argumentation structure is captured using ARTOO (www.
york.ac.uk/ycil/software/artoo), our Web-based tool for constructing
fitness-for-purpose arguments, using a notation based on the safety-critical
goal structuring notation. We show how argumentation helps in making
the design and structured analysis of a model transparent, capturing
the reasoning behind the inclusion or exclusion of each biological feature
and recording assumptions, as well as pointing to evidence supporting
model-derived conclusions.
 on March 9, 2015ttp://rsif.royalsocietypublishing.org/1. Introduction
The application of computational and mathematical models is a generally
accepted technique in physical sciences and engineering, yet was met with
scepticism by experimental biologists [1]. With advances in computational
power, the development of new modelling techniques and methodologies,
and the promotion of interdisciplinary research, traditional biological studies
complemented by the use of in silico predictive tools is now becoming more
prevalent. Computational models have the capacity to provide an interpretation
of biological data and act as a scientific tool through which new hypotheses can
be established and explored [2,3]. Furthermore, computational tools allow
virtual experimentation not bound by the ethical and financial constraints
associated with laboratory studies.
Computational techniques can appear to be opaque tools that provide a
researcher with a result or prediction but little understanding of how the
result has been reached [4]. The application of scientific software continues to
be discussed in journals [5,6], with concerns that researchers place too much
trust in published software, and suggestions that code, as well as methods
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about adequacy of software engineering is appropriate, but the
same focus needs to be applied to the underlying biological
information from which a computational model is been con-
structed. In the course of implementation, decisions are made
concerning the interpretation of available biological data, how
that biological data will be translated into a form that can be
effectively expressed on a computer; and which assumptions
orabstractions are to be employed tomask gaps in the biological
understanding. An appreciation of the underlying biological
information and the ways in which it is used in the compu-
tational model is critical to the sensible interpretation of
computational results in the context of the biological domain.
However, it is rare to see a published model of a biological
systemaccompanied byany in-depthdescription or justification
of the decisions made in development. While much focus has
been given to the release of software tools that aid researchers
in developing and analysing computational models [8–13],
the same attention has not been given to providing researchers
with a means of showing that their developed tool can ade-
quately support the investigation of a specific biological
research question: that the tool is fit for purpose.
We have previously developed a computational model, or
simulation, of pre-natal lymphoid tissue formation to help
direct and understand results of laboratory experimentation
[14,15]. Through the use of a cell culture system, the behaviour
of cells was tracked for a period of 1 h, after which key cell be-
haviour responses were calculated. These responses revealed
that there is a statistically significant change in cell behaviour
when in the vicinity of developing lymphoid tissue [14]: the
reasons for which are currently unclear. Our computational
model adopts an agent-based approach, allowing exploration
of how system dynamics, in this case changes in cell behaviour
responses, might emerge from interactions between cells and
their environment [15,16]. For the full detail of our implemen-
tation, we direct the reader to our previous descriptions of the
biological information captured in the model, and the manner
by which this has been translated into a specification that can
be encoded as a computer program and simulation platform
[14,15]. As a brief overview for the purposes of this paper,
three cell populations are known to be involved in lymphoid
tissue development, counts of which have been calculated
from flow cytometry experiments. Other attributes, such as
cell speed, have been determined from either laboratory exper-
iments or from the literature. Our model captures each of these
cells: each of which possesses individual attributes and state.
Transitions between these states are described in a set of rules,
described in detail in unified modelling language (UML) state
diagrams [15]. With each simulation time-step, cell behaviour
is simulated dependent on the current state of the cell and the
cell’s location. The environment, in this case the developing gas-
trointestinal tract, is modelled as a continuous space, with
dimensions set that are representative of measurements taken
from stereomicroscopy images. Simulated adhesion and chemo-
kine diffusion pathways influence the behaviour of these cells,
causing the emergence of aggregations of cells within the simu-
lated environment: aggregations that become lymphoid organs.
Our previously published studies demonstrate that we could
use simulation to reproduce emergent cell behaviour that is stat-
istically similar to that observed in ex vivo culture, thus
providing us with a strong baseline behaviour from which we
can use the tool to explore the mechanisms underlying tissue
development [14,15]. Through careful statistical analysis ofsimulation behaviour, including sensitivity analyses [13], we
were able to identify key pathways in the simulated model
and suggest how the existence of such pathways in the biologi-
cal system could be investigated in the laboratory. However, as
for any model, the simulation and its results are heavily influ-
enced by the implementation decisions taken when our
simulator was developed.
In general, simulations of complex systems, including
biological systems, are difficult to describe: it is hard to explain
and justify complex interactions, either in real biological sys-
tems or in simulations. Toxicology and human risk
assessment studies, for example, use adverse outcome path-
way (AOP) tools to demonstrate existing understanding of
how molecular, cellular, organ and organism interactions
link a molecular initiating event with a particular adverse out-
come, such as skin inflammation [17]. This information,
derived from the literature or experimental studies, is analysed
and presented as a flow diagram. The strength of the evidence
supporting each event, which may be established as well as
hypothetical or predictive, is evaluated and accompanies the
diagram. Yet, AOPs have been criticized for providing a rep-
resentation of the toxicological process that is simplistic [17],
splitting the representation of the process and the evidence.
For the description of computational models, both unified
modelling language, adopted in the development of computer
software, and systems biology mark-up language (SBML) may
be applied [18–20]; the latter possessing the benefit of allow-
ing model execution by a number of SBML-supported
software tools. Both however are limited by restrictions in
the extent of the system they can capture: UML lacks the form-
alism to capture some biological features (such as cyclic-
feedback) [21], and SBML cannot currently describe complex
agent-based models. In addition, both are purely descriptive:
neither provides complete, evidence-supported detail stating
how that model has been composed. In ecology, the ODD
(overview, design concepts, details) protocol is starting to
address this, through application of a standard protocol com-
pleted while implementing a computational model, with the
aim of ensuring reproducibility of results [22]. The ODD pro-
tocol addresses the purpose behind the creation of the
model, details the inclusion of each biological component of
interest (e.g. cell type) and defines submodels that describe
how observed biological behaviour and attributes are
implemented. Any specific assumptions underlying the
implemented behaviour are also recorded. The ODD authors
note that completion of the protocol provides researchers
with all the information they require to run the simulation
and reproduce the published results: the level of information
required for a typical methods section of a publication [22].
Yet, ODD also does not provide a motivation and justification
for the detailed model and implementation. Scientific repeat-
ability is addressed, not fitness for purpose. The ODD
authors also state that, within the protocol, there should be
no recording of information concerning experimental scen-
arios, simulation experiments and results from statistical
techniques such as sensitivity analyses: these should be
recorded and published separately [22]. However, we contend
that having such information within the simulation design is a
key part of an argument of fitness for purpose that convinces
researchers the simulation is appropriate for the studies in
which it will be applied.
Here, we present the use of a structured argumentation
approach that assists the researcher in recording justifications
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process that underlie the development of a computational
model, to assist others in interpreting the predictions that
model generates. We suggest the adoption of this approach
within an existing process of computational model develop-
ment, for example that suggested in [3,15], yet acknowledge
the potential for a researcher to use constructed arguments
as a guide for alternative processes of model development.
The argumentation approach is widely applicable and is
independent of the choice of techniques used for model
description: it can be applied to models described in notations
such as UML or SBML and to models accompanied by ODD
or AOP descriptions. Our approach takes inspiration from
the field of safety-critical systems: like biological systems,
safety-critical systems comprise complex interactions, within
a system, between systems and with the wider environment.
In critical systems engineering, a system cannot be declared
safe, but can be demonstrated to be ‘as safe as reasonably prac-
ticable’ [23]. Prior to the adoption of safety-critical systems
(e.g. aircraft, certified by military or civil aviation authorities),
it must be shown that the system and its development meet
stringent compliance requirements: hazards must be shown
to have been identified systematically and thoroughly, and
mitigated to an appropriate level. Acceptable safety can be
established and presented using arguments over evidence.
We have adapted this technique to give a structured argumen-
tation approach that can be used to demonstrate acceptable
fitness for purpose. In common with acceptable safety, our
argumentation approach aims to capture and expose reason-
ing, via an argumentation structure, to critical scrutiny, in
order to establish trust in simulations [24,25]. While it may
seem unnecessary to use techniques from aircraft safety in bio-
logical simulation, we note that errors or misinterpretation of
simulation results may have significant, possibly even safety-
critical repercussions if, for instance, a simulation is used as
a key decision-making tool in clinical trials [26,27]. Opening
all simulation design and implementation decisions to critical
scrutiny requires that elements captured in the model be trace-
able to the biological domain, and their inclusion justified with
respect to abstraction levels and the purpose of the simulation.
Drawing on safety-case argumentation, we create a dia-
grammatic summary of the structured argument of fitness
for purpose, using a visual notation closely based on the stan-
dard safety-critical argumentation notation, goal structuring
notation (GSN) [28,29]. The argument is presented as a tree
of connected argument components, starting from a top-
level claim (a GSN goal). The researcher identifies a set of
fitness-for-purpose requirements (referred to as goals or
claims, that the argument seeks to substantiate), and a set
of strategies that can be used to assess whether the require-
ment has been met. The strategies typically break goals
down into subgoals, and eventually link to evidence sup-
porting the claim, alongside the source of the evidence,
where appropriate. In the simulation context, the GSN argu-
ment structure summarizes the biological information upon
which the model has been constructed, opening this to cri-
tique. GSN also allows goals to be linked to assumptions
and justifications. If a requirement cannot be fully supported
by available evidence, for example where there are gaps in
the biological understanding, then the assumptions and
abstractions made in place of this evidence are documented,
opening all implementation decisions to scrutiny by other
researchers in the field and identifying areas of biologicalstudy that have been overlooked or require further laboratory
work. In addition, and in contrast to the ODD protocol
described above, argumentation approaches can be applied
not only to simulation development, but also to design and
sensitivity analyses and simulation experiments.
One notable side effect of focusing on the justifications for
a simulation model is to engage researchers from differing
disciplines in the process of capturing the model to be imple-
mented. Following sound software engineering principles, we
can express the model in structures and language that is not
discipline dependent, and then provide an argument that the
implementation conforms, in a traceable, repeatable manner, to
this model as part of the overall fitness-for-purpose argument
[30]. Constructing the argument using a visual notation results
in a document that can be easily interpreted by researchers
across disciplines, and which can be published alongside the
description of and results from the simulation. The overarching
objective of this approach is to increase confidence in the use
of simulation-derived predictions, potentially increasing the
impact of a simulation study. While it is possible that providing
a detailed rationale behind simulation development might risk
limiting a researcher’s willingness to challenge the results of
work supported by argumentation, we feel this technique has
the potential to address an important void in biological simu-
lation development: the provision of a method by which a
researcher can fully appreciate the thought processes behind
model composition. In biological contexts, the rationale is
never a fullyexplored, uncontentious argument, because the con-
text is not that well understood. Instead, the argument exposes
the rationale and understanding to critique, initiating a healthy
debate about the quality of the experimentation and the results.
To support both our adoption of the argumentation
approach and to encourage wider use of argumentation
in conjunction with simulation-based research, we have
developed a freely available Web-based argumentation
tool, ARTOO (www.york.ac.uk/ycil/software/artoo). Here,
we demonstrate argumentation, and the use of ARTOO, by pre-
senting the argumentation that supports our simulation of
lymphoid organ development [13–15]. We present our
implementation decisions and expose to scientific scrutiny
the case that our simulation is fit for the defined purpose of
our published study. We demonstrate the power of the
approach in providing an accessible description of the detail
and rationale of a simulation of a biological system, ensuring
anyone using our model can see clearly how the biological
information has been used and can assess the impact our
assumptions and abstractions have on simulator response.
The ARTOO tool, the description of the GSN-like notation and
the case study together make it possible for researchers to
adopt the argumentation technique, with the objective of
increasing confidence in the application of computational
modelling and predictive tools.2. Material and methods
2.1. The biological case study: lymphoid tissue
development simulator
Through the adoption of an agent-based modelling approach, we
have developed a computational model, or simulation, of lym-
phoid tissue development in pre-natal mice [14,15]. Populations
of haematopoietic cells migrate into the developing gut from
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adhesion factor expressing stromal cells 72 h later [31–33].
These aggregations mature to form lymphoid organs capable
of triggering adaptive immune responses to pathogens. Cell
observations captured in ex vivo culture at hour 12 of develop-
ment (velocity and displacement) reveal that haematopoietic
cells behave in a statistically significantly different manner
when in the vicinity of a developing aggregation [14]. Although
a basic model of tissue formation has been developed through
laboratory experimentation [31,34–36], the reasons for this
emergent behaviour are not fully understood. Adopting an
agent-based modelling approach has allowed us to simulate
the behaviour of each individual cell within a simulated
gastrointestinal tract environment, with each cell possessing
attributes (cell speed, size, etc.) and behavioural characteristics
observed in the laboratory or in the literature. Data analyses
suggest that there is no statistical difference between the emer-
gent behaviour of cells in the ex vivo culture system and our
simulated haematopoietic cells [14]. This result, combined with
a rigorous statistical analysis of simulation behaviour [13] has
provided us with a tool that we have used to develop and test
hypotheses that can inform future laboratory investigations.
2.2. The argumentation tool: ARTOO
ARTOO was developed to provide an argument-driven platform for
presenting a stringent analysis that the design and implementa-
tion of a computational model of a biological system is fit for
purpose (figure 1). This permits the construction of an hierarchical
argumentation structure using a GSN-like, graphical notation.
The tool released is under a GNU GPL3 licence, is freely accessible
via www.york.ac.uk/ycil/software/artoo and runs in an up-to-
date version of the Chrome and Firefox browsers. To encourage
adoption of the approach, full instructions are available along-
side the tool and the argumentation structures in this paper can
be loaded into the argumentation design window for further
exploration. Argumentation structures developed in ARTOO can
be extracted as high-quality PNG images that can be published
alongside a description of a developed simulation. Evidence that
may be located elsewhere, such as in publications or in statistical
analyses, can be embedded within the structure through use of
hyperlinks, making all the argument information available to a
researcher analysing the implementation.
2.3. Constructing an argument
An argument is developed as a hierarchical decomposition of
claims relating to the purpose of the simulation. The goal of
the argument is to support a claim, ultimately with evidence if
possible, while keeping a record of the context of that claim.
The first step in constructing any argument is to identify the
top-level claim that we are seeking to establish and its context.
The context of a top-level claim in a fitness argument needs to
clarify the purpose of the simulation and define key terms. The
context is connected to the claim with lines with white arrow-
heads. Components supporting the top-level claim, explained
next, are connected with lines with solid arrowheads.
Connections between a top-level claim and supporting sub-
claims are made via a strategy node. This strategy should
detail the steps that will be taken to argue that the top-level
claim is supported. These strategies may in turn lead to the defi-
nition of further claims, subclaims, that are then argued in turn.
Examining a subclaim increases confidence that its parent claim
holds, and all subclaims are considered together when making
an overall judgement on whether the top-level claim is met.
Some subclaims can be substantiated by pointing to evidence,
such as statistical results or published research. Whereas in
safety-critical safety cases, where all claims must ultimately be
substantiated by evidence, fitness arguments allow us to marksome undeveloped claims. This allows us to indicate uncertainties:
areas where the biological knowledge is missing or incomplete,
or where further biological experimentation can be usefully
undertaken. Undeveloped claims should not be seen as a weak-
ness in the simulation, but as a clear statement that the researcher
has recognized a gap in understanding, and addressed these in a
particular manner (through use of assumptions or an abstrac-
tion). Claims that cannot be substantiated are accompanied by
a white diamond.
When each identified claim and subclaim has been documen-
ted, the argument structure summarizes how the researcher
believes the top-level claim can be substantiated. Reviewers and
collaborators can peruse the structure to gain an appreciation
of the link between the biological system and the simulation,
and to identify any areas where the simulation authors can be
challenged to improve their argument [37].3. Results
3.1. Arguing fitness of the lymphoid development
simulator using ARTOO
We present our argument that our lymphoid tissue develop-
ment simulation [14,15] is an adequate representation of the
biological system, and thus fit for the purpose of studying
haematopoietic cell aggregation. Figure 2 shows the top-
level claim, that ‘our model is an adequate representation of
the biology’, and its immediate subclaims. To begin the pro-
cess of arguing that this is the case, we explicitly state what
we mean by an adequate representation and state the pur-
pose behind the implementation of the model: a vital
consideration when determining what simulation results
mean in the context of the biological system. The rationale
for substantiating the top-level claim is stated in the attached
strategies. Here, we argue over ‘the scientific context, the ade-
quacy of our abstraction and adequacy of experimental
results’. In this case, the strategy leads to four subclaims
that explore: the underlying biological data upon which our
simulation is based (claim 1.1.1); the evidence supporting
any abstractions that have been made (claim 1.1.2) and the
ability of the simulator to reproduce cell behaviour observed
in the laboratory and detailed in the literature (claim 1.1.3
and 1.1.4). The arguments supporting each of these claims
can be developed separately.
3.2. Arguing adequate representation of the biology
Figure 2 shows the expansion of claim 1.1.3, that our simu-
lated cell behaviour is representative of that observed in the
laboratory. This is a key claim in our argument: we are pre-
senting evidence to support our belief that the cell
behaviour that emerges in the simulation is representative
of the biological system. Similarly to the top-level claim, the
subclaim is accompanied by a strategy that was used to sup-
port that claim (strategy 1.1.3.1). As noted in our description
of our simulator in the Methods, through use of an ex vivo
culture system we have obtained cell behaviour observations
to which simulated cell responses can be contrasted [14].
We make further subclaims in figure 2 that the behaviour
captured in this system is statistically similar to that observed
in simulation, for both cells close to (less than 50 mm) and
far from (more than 50 mm) a forming aggregation of
haematopoietic cells. For full transparency, we state the stat-
istical test that we have used in this comparison, and a
(b)
(a)
claim
the goal of the
argument that
we are seeking
to support
the steps that will
be taken to argue
that the claim is
supported
defines the
purpose of the
argument and
key terms
provides a
reasoning behind
the selection of
a strategy or claim
provides an
explicit statement
of any assumptions
made in place of
biological
understanding
undeveloped claim:
a claim that
cannot currrently
be supported due
to incomplete
evidence
expanded claim:
a claim that
for space reasons
is expanded upon
in a separate
diagram
evidence that
supports the
argument made
in the attached
claim
solution
assumption
A
J
strategy context justification
Figure 1. (a) A screenshot of the ARTOO argumentation tool. This runs in a Web browser window in an up-to-date version of either Chrome or Firefox browser (other
browsers do not fully support the required technologies). The File menu provides three options: open a previously developed ARTOO argument structure; save an
argument structure, export the current argument structure as a PNG image. The Build menu provides options to create, edit and delete nodes (representing argu-
ment components); and to create or delete connections among nodes. The View menu operations enable zooming in, zooming out and centring of the argument
structure. Nodes in the argument structure can be individually moved using the computer mouse by left clicking and dragging the node. Left mouse clicking and
dragging on areas outside of the nodes will drag the entire structure. Right mouse clicking on an argument node (shown in the screenshot on the ‘Assumptions’
node) allows access to a node-specific menu to edit or delete the node, add or delete a connection to that node, or collapse and hide the nodes below this node in
the tree. A collapsed section of an argument is denoted by a black diamond symbol. (b) Definitions of each node type available in goal structuring notation.
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experimental work using model
produces statistically comparable results
to those seen biologically
model is an adequate
representation of the biology
– recreate emergent observed in vivo and ex vivo
– creation of tool for exploration of hypotheses
definition: ‘adequate’ claim 1:
underlying biological data
is adequate/accurate
claim 1.1.1:
the abstraction (platform model)
is adequate representation
claim 1.1.2:
simulated cells <50 mm from a forming
patch behave as observed ex vivo
claim 1.1.3.1.1:Mann–Whitney
U-test used as no
guarantee that the
data are normally
distributed
Mann–Whitney
test reveals no
statistical
difference [14]
Mann–Whitney
test reveals no
statistical
difference [14]
justifications:
simulated cells > 50 mm from a forming
patch behave as observed ex vivo
claim 1.1.3.1.2:
J
simulation captures cell aggregation
emergent behaviour at 72 h
claim 1.1.4:
cell behaviour observed in
simulation can be compared to
that observed in cell culture
using statistical techniques
definition: representative
simulated cell behaviour between
12 and 13 h is representative of
that observed in ex vivo culture
claim 1.1.3:
argue over scientific content, the adequacy
of the abstraction, and experimental results
strategy 1.1:
argue that simulated cell behaviour is
statistically similar to that ex vivo at 12 h
strategy 1.1.3.1:
purpose:
Figure 2. Top-level of argumentation structure used during the development of a computational tool that captures Peyer’s Patch development, as output by our
ARTOO. The tool enables the developer to capture their claims and evidence using GSN. A claim is made that the simulation is an adequate representation of the
biology, and arguments stated that support this claim. In turn, this claim is split into four subclaims. A black diamond notes that the claim has been developed yet
is shown in the following figures due to limitations on space. Claim 1.1.3 has been developed in this figure, noting the evidence that simulated cell behaviour at the
12 h time-point is statistically similar to that observed ex vivo. Where a goal is stated, the tool enables the developer to link the goal to the evidence that supports
the claim. Here, the figure is demonstrating that this evidence is within selected publications.
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cal test for drawing this conclusion. Finally, we show the
evidence that supports the structure of claims (in circles):
Mann–Whitney U-test statistics that reveal no statistical
difference between the behaviour of cells in the simulation
and that in the laboratory, with a note stating where the bio-
logical data we have used to draw this conclusion can be
located. In ARTOO, hyperlinks can be used to link to such
supporting evidence.3.3. Biological data: availability, adequacy and accuracy
Whereas claim 1.1.3 above details how the simulation result
compares with specified biological data, claim 1.1.1 (figure 3)
examines the adequacy and accuracy of the biological data
upon which our simulation has been constructed. The argu-
ment summarizes the specific biological data that has been
used in the implementation, the source of these data, and
where applicable, assumptions relevant to that data.
The claim in figure 3 is supported from evidence generated
from four argumentation strategies, each concerning a subset
of simulation parameters derived from biological data: proper-
ties of haematopoietic (LTin/LTi) cells; properties of stromal(LTo) cells; representation of the intestine environment and
haematopoietic cell aggregation characteristics. The objective
of the argument under this claim is to document the link
between the simulation implementation and the real-world
domain. Thus, available flow cytometry data, stereomicro-
scopy measurements and data mined from the literature are
all included to support subclaims that the simulation has
been built on appropriate data. The argument ensures it is
clear how we have used these biological data to derive simu-
lation parameters. For example, we explain how we convert
flow cytometry data into estimates of cell numbers through
the time course of the simulation. This record of what data
were used, and how, is an important information for a
researcher to have when conducting a full statistical analysis
of the effect that a parameter has on a simulation response.
As previously noted, there are many interesting biological
questions for which no data are yet available. Our structured
argumentation approach clearly indicates where evidence to
support a claim is not yet available: identifying potential
areas requiring further investigation. For example, claim
1.1.1.4.2 in figure 3 has a blank diamond appended, showing
that it is an undeveloped claim, because there was not, at the
time of simulation development, any quantitative biological
cell size
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cell size
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results from
E15.5: 20% of
cells LTi [15]
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LTi [15]
flow cytometry
results from E15.5:
0.45% of cells
LTin [15]
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simulated gut environment
can be related to
biological measurements
claim 1.1.1.3.1:scale set where
1 pixel = 4 mm
context:
scale set where
1 pixel = 4 mm
context:
A
A
A
J
scale set where
1 pixel =
4 mm
context:
taking measures
at E15.5 and
E16.5 ensures a
rate of gut growth
can be calculated
assumptions:
cell velocities are
normally distributed
[14]. Simulated cells
assigned speeds using
Gaussian number
generator
justification:
claim 1.1.1.1.1:
Figure 3. Expanded argumentation structure for claim 1.1.1 in figure 2. The argument was created during the development of a lymphoid tissue development
simulator that captures Peyer’s Patch development. The claim argues that the biological data against which the simulation is judged are adequate. Where a claim is
stated, the tool allows the developer to link the claim to evidence that supports the claim. In the majority of cases, evidence is provided to substantiate the claim.
However, where data are unavailable, the claim cannot be substantiated, shown by a blank diamond.
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objectively compare to the simulated aggregations that form
in silico. A researcher assessing our model can clearly see that
we are not claiming to produce aggregations of haematopoietic
cells that are quantitatively similar to that observed in vivo.3.4. Engineering: justifying model abstractions
Concerns over the modelling of a biological system that is
incomplete is one criticism often levelled at simulation. In
scenarios where this is the case, or the biological knowledge
is sufficient yet modelling the full detail is not computationally
feasible, abstractions need to be made. The impact these
abstractions have on simulation response needs to be analysed
and understood, in order that researchers can translate
simulation results into meaningful biological hypotheses.
Figure 4 shows the argument supporting claim 1.1.2 of
figure 2, that the abstractions made in our model of lymphoid
tissue development are appropriate. The abstractions in this
specific case had to be made due to an incomplete under-
standing of chemokine expression and adhesion factor
expression. While the generally accepted model of lymphoidtissue development suggests that haematopoietic cell aggre-
gation is driven by the expression of three chemokines
binding to two receptors on haematopoietic cells, other
published research suggests that only one chemokine
causes a significant difference in the formation of cell aggre-
gation [38,39]. As such, we have made the abstraction that a
pathway consisting of one chemokine and one receptor is suf-
ficient to capture this mechanism. As detailed in the top left
of figure 4, studies in the literature suggest that this may be a
suitable abstraction to make, as the inhibition of receptor
CXCR5 causes a significant difference in the formation of
cell aggregation [38], yet there is no significant difference
where the CCR7 receptor is inhibited [39]. Similar abstrac-
tions have been drawn for adhesion factor expression, with
experimental results suggesting that as one adhesion path-
way has a more significant impact on cell aggregation [40],
others can be abstracted from the simulation. A stringent
analysis of each abstraction has provided us with a method
to document these abstractions for full scientific scrutiny,
allowed us to justify why these have been made with sup-
porting evidence and to direct researchers assessing our
simulation to that available evidence.
domain
expert insight
domain
expert insight
domain
expert insight
cell behaviour
calibration
results [14,15]
domain
expert insight
no significant
difference in mice
lacking receptor
CCR7 [39]significant difference
in PP formation if
CXCR5 inhibited [38]
significant difference
in PP formation if
VCAM-1 inhibited
[40]
no quantitative data
exist at the current time
context:
level of expression of
adhesion replicates that
in the biological system
claim 1.1.2.2.2:
capturing one chemokine
is sufficient to capture
emergent behaviour
claim 1.1.2.1.1:
levels of expression of
chemokines replicates that
in the biological system
claim 1.1.2.1.2:
the abstraction (platform model)
is adequate representation
claim 1.1.2:
argue that chemokine
expression is adequately
captured in the simulation
strategy 1.1.2.1:
argue that adhesion factor
expression is adequately
captured in the simulation
strategy 1.1.2.2:
argue that the platform
representation of the gut
environment is appropriate
strategy 1.1.2.3:
argue that the abstractions made
concerning cell interaction do not
affect emergent behaviours
strategy 1.1.2.4:
the physical shape
of the gut has no
impact on PP formation
claim 1.1.2.3.1:
it is not necessary to explicitly
capture lymphotoxin signalling
claim 1.1.2.4.1:a two-dimensional
representation is
suitable to capture the
emergent behaviours
claim 1.1.2.3.2:
capturing one
adhesion factor
is sufficient to
capture emergent
behaviour
claim 1.1.2.2.1:
1. LTin and LTi cells
express two adhesion
receptors, a4b1 and
a4b7, that bind to
VCAM-1, MAdCAM, and
ICAM-1 expressed
by LTo cell [36]
justifications:
1. LTi cells express
two chemokine
receptors, CXCR5
and CCR7—the first
binds chemokine
CXCL13, the second
CCL19 and CCL21 [39]
2. Inhibiting CXCR5
significantly impacts
lymphoid organ
development, whereas
no significant difference
is observed when
inhibiting CCR7
justifications:
1. All cell interactions
occur on the gut
epithelium
2. All LTin/LTi cell
movement occurs on
the epithelium
3. Having a two-
dimensional aggregation
is a suitable abstraction
to judge what causes
cells to aggregate
assumptions:
1. RET signalling is thought
to upregulate LTab
signalling on LTin cells: this
occurs through stable contact
between an LTin and LTi, so is
implicitly included
2. No definitive understanding of
how LTab upregulated on LTi cells,
just that no PP form if not
upregulated [36]. Assumption
made the mechanism to
upregulate LTab is implicitly
included
assumptions:
J
J
A
A
2. Inhibiting VCAM-1
expression has a
profound effect on
aggregation, suggesting
it is dominant [40]
Figure 4. Expansion of claim 1.1.2 in figure 1. This claim examines the abstractions that have been made and whether these are fit for purpose. In this case, the
implementation of chemokines, adhesion factors, the intestine environment and cell signalling is explored.
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Subclaim 1.1.4 is expanded in figure 5. Here, we are examining
whether our simulator reproduces the second emergent behav-
iour observed in ex vivo culture: the formation of aggregations
of haematopoietic cells by hour 72 of the process. Our argu-
ment is structured over three strategies: determining whether
a representative number of aggregations is formed in the intes-
tine environment; exploring whether previously published
experimental results that examine aggregations under different
physiological conditions are replicated and showing that the
simulation captures appropriately the spatial characteristics
of aggregations. These claims are more difficult to argue,
due to the lack of quantitative biological data available. We
can show that our simulator reproduces laboratory gene
knockout experiments [31,39,41,42], but determining whether
we capture aggregation characteristics appropriately relies on
the expert opinion of our collaborating experimental biologists.
Again, our inability to objectively support the claims does not
represent a failure of the model; the argument clearly shows
our claims and evidence, which are open for scrutiny. We con-
tend that, where a simulation is developed to answer a specificquestion, the more open researchers are about the decisions
behind the implementation, the more confidence others have
in assessing the impact of simulation-derived results.
A paper description of our argumentation process makes
the approach appear static: claims have been made and justi-
fied, areas of further development have been identified and
supporting documentation produced. However, we use the
argumentation process as a dynamic and inherent part of
simulation design and results analysis. Argument develop-
ment and refinement continues as the simulator is analysed
and developed further.4. Discussion
Explorations of biological systems have used models,
whether biological or computational, to achieve various
objectives: to produce hypotheses to inform future laboratory
experimentation or clinical trials, to understand complex
datasets and to attempt to understand theories that cannot
be examined using other methods. Yet, the overriding
snapshots verified
by domain experts
calibration results
(evidence: [15])
experiments
replicated in [15],
fig. 5
simulation has been calibrated
to produce a representative
number of PP
1. Calibration is based
on setting the number of
stromal cells (LTo)
that can express RET
ligand (and thus mediate
PP development)
claim 1.1.4.1.1:
simulation captures cell aggregation
emergent behaviour at 72 h
claim 1.1.4:
comparison can be drawn
between PP generated
in silico and those in vivosnapshots verifiedby domain experts
claim 1.1.4.3.1:
representative: similar to that
observed in six mice, as shown
in [15]
definitions
assumptions:
1. There are no quantitative data
available on which simulation PP
size can be compared to in vivo
patch sizes. Thus patches are
identified by eye by collaborating
experimental immunologists
2. An analysis of the patches
identified by eye has been used
as a basis for what a patch is,
and from this a lower two-dimensional
area limit estimated. From this an
automated method of detecting
patches has been developed
justifications:
J
argue that a representative
number of PP are formed at
the end of 72 h period
strategy 1.1.4.1:
argue over the simulation’s ability
to reproduce previously published
experimental results
strategy 1.1.4.2:
argue that the simulation captures
spatial characteristics of PP
strategy 1.1.4.3:
simulation reproduces experimental
results showing patch formation
under different conditions in
[31,39,41,42]
claim 1.1.4.2.1:
Figure 5. Expansion of claim 1.1.4 in figure 1. This claim states that the simulator appropriately replicates the observed emergent behaviour: cell aggregation
indicative of Peyer’s Patch formation.
rsif.royalsocietypublishing.org
J.R.Soc.Interface
12:20141059
9
 on March 9, 2015http://rsif.royalsocietypublishing.org/Downloaded from objective is to interpret model results in the context of the bio-
logical domain. To achieve this, the researcher must
understand the mapping between the biological system
being studied and the model of that system.
Specific to biological simulations, the researcher creating
the simulation must understand the impact that decisions
made in implementation have on simulation behaviour, and
those interpreting the results must understand how these
decisions influence what that result means in the context
of the real-world system. Although a large amount of work
has been undertaken in the development of tools that aid
the implementation and analysis of simulations of biologi-
cal systems, a method for demonstrating that a simulation
implementation is an adequate representation of thebiology has yet to be adopted. This is challenging given
that simulation development should be an inherently cross-
discipline activity. Here, we have shown that the application
of a structured argumentation approach has the potential to
address this, using our previously described lymphoid
tissue simulator as an exemplar. By taking safety-critical
system engineering as an inspiration, simulation developers
can use argumentation to provide a detailed case that their
tool is fit for the clearly stated purpose for which it has
been designed, supported by available evidence.
Where these tools are applied as part of a key decision-
making process or for hypothesis generation, such as drug
development, a clear rationale for the fitness for purpose of
the model is essential.
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requirements using GSN produces a diagrammatic summary
that can be created and interpreted by researchers across the
disciplines, opening the implementation to scrutiny by exper-
imental biologists as well as simulation developers. We have
previously advocated a principled approach to simulation
development where a number of models are developed: a
model consisting exclusively of the biological information to
be captured, a translation of this model into a specification
that can be encoded as a simulation, an executable of that spe-
cification and a model detailing how simulation-derived
results will be interpreted in terms of the biological domain
[15,43]. By creating argumentation structures at each stage of
simulation development, each step in the simulation develop-
ment is made transparent, the reasoning behind the inclusion
or exclusion of a biological feature or assumption is provided
and evidence given as to why this conclusion has been drawn.
By including descriptions of experiments that have been per-
formed using the simulation, other researchers are equipped
with all the detail required to repeat these experiments, to
judge their contribution to their own research. The choice of
biological data upon which the simulator is run, and how
the result has been interpreted, is made explicit. Specific
areas where the current biological understanding is lacking
are identified (as undeveloped claims), and the abstractions
introduced are explained and justified. An effect of the unco-
vering of incomplete knowledge is viewed as necessarily
making a model unfit for purpose: instead, the process of
argumentation highlights where biological experimentation
might be focused to improve understanding [44]. These
aspects have an impact on the result generated by the simu-
lator, and thus will impact how this result is translated in
the context of the real-world domain.
The field of safety-critical systems, from which this
approach takes its inspiration, has an argumentation-based
culture: one which if adopted by those developing simu-
lations of biological systems, could increase the confidence
in the application of computational predictive tools [44].
The adoption of such a culture, and such rigour in modeldesign, could also not be restricted to those developing simu-
lations, yet contribute to much wider discussions concerning
the relationship between any model and the biological system
it represents. The criticisms often directed towards simu-
lation-based models are beginning to be levied towards cell
culture and animal models, with studies questioning how
representative these traditional biological models are of the
system they have been designed to represent: the human
[45,46]. The scope of this paper only considers the impact
that a structured argumentation process could have on simu-
lation-derived research, yet the scope for impact outside this
area should not be underestimated.
To encourage researchers to adopt an argumentation
approach, we have released ARTOO. We have demonstrated
the use of ARTOO in the production of the argumentation
structures which support the case that our lymphoid tissue
development is fit for the purpose for which it was designed:
to provide biologically relevant hypotheses as to why cell be-
haviour becomes statistically different in the vicinity of initial
haematopoietic cell aggregations [14]. Through the use of
argumentation, we clearly summarize the biological data
upon which our simulation is based, the manner in which
we have derived assumptions from this and instances
where we have made abstractions in the absence of biological
data. As predictions are being made that aim to be grounded
in the biological domain, this information is vital to researchers
intending to understand the impact of our results.Funding statement. This work was part funded by the Wellcome Trust
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